Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses

Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where ...

Source: Radiation Oncology - March 13, 2019 Category: Cancer & Oncology Authors: Jianjiao Ni, Guodong Li, Xi Yang, Li Chu, Jialei Wang, Yida Li, Liqing Zou, Yuan Li, Congying Xie and Zhengfei Zhu Tags: Research Source Type: research